Jared Kaltwasser

Mass spectrometry technology identified proteomic biomarkers of IPF, but more work will be needed to fully translate these findings to the clinic.

Traditional Chinese medicine relies on nonlinear, unstructured data, but a new report suggests its practitioners can still benefit from machine learning, including in the treatment of idiopathic pulmonary fibrosis.

Respiratory syncytial virus (RSV) remains a leading cause of acute bronchitis in children, but new research may enable earlier intervention.

Real-world evidence highlights the effectiveness of lisocabtagene maraleucel in treating relapsed or refractory chronic lymphocytic leukemia (R/R CLL).

Chronic inducible cold urticaria is rare, but a new study suggests it can have significant impacts on patients’ daily lives.

With a follow-up of up to 6 years, the median progression-free survival for long-term extension participants was 52.5 months.

The benefit of trabectedin plus olaparib to all-comers with soft tissue sarcoma was marginal, but the response was more pronounced in certain subgroups.

Patients with DLBCL who were treated with R-CHOP and quickly relapsed or were refractory to therapy had poor outcomes on second-line therapy.

The patient was a rare case of a patient with dedifferentiated liposarcoma and a high tumor mutational burden.

Patients with pulmonary fibrosis (PF) obtain much of their information from the internet, a new report finds, even though a significant amount of information on the internet is incomplete or inaccurate.

Developers say more accurate automated multiple sclerosis lesion segmentation can improve research and patient care.

There is no cure for chronic lymphocytic leukemia, but an array of new therapeutic strategies are improving outcomes for patients.

More than one-quarter of US adults have a risk factor for severe RSV infection, but their eligibility for the RSV vaccine depends on their age.

Global chronic lymphocytic leukemia incidence and mortality is declining, but the disease’s prevalence has increased modestly.

New research shows patients commonly take lower doses of nintedanib, and the majority are also taking immunomodulatory drugs.

In real-world usage, 97% of cases of cytokine release syndrome following treatment with lisocabtagene maraleucel happened within 15 days of infusion.

TAM receptors could emerge as promising therapeutic targets for rheumatoid arthritis, offering insights into immune regulation and potential treatment strategies.

Patients with elevated levels of multiple adipokines had the highest risk, the authors found.

New research comparing the safety profiles of the 2 multiple sclerosis therapies suggests ocrelizumab is associated with lower rates of all-cause hospitalization and hypogammaglobulinemia.

Combining genetic features with clinical data improved the performance of a pulmonary fibrosis prediction score for people with rheumatoid arthritis.

Chimeric antigen receptor T-cell therapies, along with bispecific antibodies, have changed the treatment paradigm for patients with relapsed or refractory mantle cell lymphoma.

A new analysis based on two prospective trials helps clarify the roles of chemotherapy and radiotherapy.

Immunoglobulin heavy chain variable is an important prognostic biomarker in chronic lymphocytic leukemia, but the authors of a new review say its role has yet to be fully understood.

The causes of financial hardship among people with rheumatoid arthritis are not necessarily based on the cost of disease-modifying therapies, according to new research.

Only about 2% of cases of rhabdomyosarcoma primarily arise from the chest wall, and such cases require careful planning.

An RNA-based therapeutic approach led to transient activation of telomerase activity in a model of pulmonary fibrosis.

Nerandomilast slowed disease progression at 2 doses compared with placebo among US participants in the trial.

The study underscores the importance of repeat testing in cases where myelin oligodendrocyte glycoprotein immunoglobulin G tests are borderline.

Though patients with type 2 diabetes or chronic kidney disease (CKD) face a greater risk of heart failure (HF) following acute myocardial infarction (AMI), patients without those comorbidities also benefit from empagliflozin.

Real-world data suggest metabolic dysfunction-associated steatotic liver disease is also associated with higher all-cause mortality.